Retinopathy associated with interferon therapy in patients with hepatitis C virus

Mahmoud Abd El-Badie Mohamed1
Khaled Abd-El azeem Eed2
1Ophthalmology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt; 2Gastroenterology and Hepatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt

Purpose: To evaluate retinopathy associated with interferon therapy in patients with chronic hepatitis C.

Methods: One hundred patients with chronic hepatitis C undergoing interferon therapy were examined for the presence of cotton wool spots, retinal hemorrhages, cystoid macular edema, capillary non-perfusion, and arteriolar occlusion. Complete ophthalmological examination including indirect ophthalmoscopic fundus examination was carried out for all patients and colored fundus photography and fluorescein angiography were carried out for the patients with positive fundus findings. The follow-up period was 9 months.

Results: Sixteen percent of patients developed retinopathy in the form of cotton wool spots, retinal hemorrhages, cystoid macular edema, and capillary non-perfusion.

Conclusion: Interferon therapy can lead to retinopathy which is mostly reversible and dose related. Periodic fundoscopic examinations help in early detection and prevent progression to permanent visual loss.

Keywords: retinopathy, interferon, hepatitis C, complications

Introduction
An estimated 170 million people worldwide have hepatitis C virus (HCV) infection and over 20,000 new cases emerge every year. HCV infection frequently persists and may cause cirrhosis and hepatocellular carcinoma. In the US and most developed nations, where the prevalence of infection is 1%–2%, HCV is the leading cause of chronic liver disease.1

HCV infection is a serious public health problem in Egypt, and is the country with the highest HCV prevalence, where 10%–20% of the general population is infected.2

Interferons are a group of glycoproteins that modulate the activity of the immune system. Recombinant alpha-interferon (IFN) has recently been approved as a therapy for chronic hepatitis C, for its antiviral effects and inhibition of cell proliferation.3

Although interferon-based therapy is widely used for the treatment of chronic HCV, it is not without its disadvantages. Treatment duration lasts for months, and is often fraught with potentially dangerous side effects. Some of these side effects, such as influenza-like illness, myalgias, depression, and cytopenias can be intolerable resulting in premature treatment cessation, but have no lasting effects. Ocular complications are among the complications of interferon therapy and include retinal hemorrhages, cotton wool spots, loss of color vision, cataracts, glaucoma, and occasionally retinal
artery or vein obstruction. Although the incidence of ophthalmological disorders while on interferon therapy is low, this can result in loss of vision.4–11

Patients and methods
In this prospective case series study, one hundred patients with chronic hepatitis-C under Interferon (INF) therapy were consecutively recruited from patients attending the outpatient ophthalmic clinic at the University Hospital, Faculty of Medicine, Al-Azhar University, Assuit. The research followed the tenets of declaration of Helsinki. The study protocol was approved by the Ethics Committee at Al-Azhar University Hospital. Written informed consent was obtained from all patients included in the study, and then in addition to the medical and laboratory examination, all patients were subjected to full ophthalmological assessment to evaluate the retinopathy associated interferon therapy.

Inclusion criteria were: (1) seropositivity for anti-HCV antibodies determined using ELISA; (2) first use of interferon therapy.

Exclusion criteria were: (1) previous interferon therapy; (2) patients with hepatitis B; (3) patients with decompensated liver; (4) patients with renal failure; (5) patients with cardiovascular disorders such as coronary insufficiency, congestive heart failure, and ischemic stroke; (6) patients with a dense cataract, visual field abnormality, glaucoma, or any other ocular abnormalities.

Evaluation before treatment:
A. History of visual loss, hazy vision, and ocular disease or ocular surgeries
B. Ophthalmological examination: (1) best corrected visual acuity (BCVA) measured using Landolt’s broken rings; (2) pupillary reaction (direct and consensual) and if there is afferent pupillary defect; (3) full slit-lamp examination; (4) intraocular pressure (IOP) measured by Goldmann’s applanation tonometer; (5) fundus biomicroscopy (carried out after maximum pupillary dilation by a combination of tropicamide 1% eye drops and phenylephrine 2.5% eye drops using both slit-lamp biomicroscopy with non-contact +90 D Volk lens and/or Goldmann contact lens); (6) examination of the retinal periphery using an indirect ophthalmoscope.
C. Medical examinations and abdominal ultrasonography.
D. Investigations: (1) Ocular; both colored fundus photography and fundus fluorescein angiography (FFA); (2) Laboratory (including enzyme-linked immunosorbent assay (ELISA) test for hepatitis surface Ag and Ab; polymerase chain reaction (PCR) for hepatitis C virus RNA; Full blood count; prothrombin time; direct and indirect bilirubin; fasting blood sugar; serum creatinine; liver enzymes (serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase; alanine aminotransferase.

Treatment protocol
Patients were treated with pegylated interferon α-2a at a dose of 180 mcg injected subcutaneously once weekly for 48 weeks. Ribavirin was given orally 800–1200 mg/day according to body weight.

Follow-up
All patients underwent clinical and laboratory assessments, ophthalmic examination, at 15 days, 1 month, 2 months, 3 months, 6 months, 8 months, and 9 months after the start of IFN treatment.

Results
Initially, 120 patients fulfilled the criteria for IFN therapy, but 20 of them were excluded due to non-compliance with the follow-up visits and due to the presence of diabetic or hypertensive retinopathy. Also, two patients died during the study time, due to a disease not related to hepatitis, so these patients are not included.

Therefore, a total of 100 patients (68 male and 32 female), with chronic HCV were selected. The mean age was 46 years.

After the start of interferon therapy, 16 out of 100 patients (16%) developed retinopathy which was bilateral in 12 (75%) patients and unilateral in 4 (25%) patients.

Retinopathy was initially diagnosed by the appearance of a cotton wool spot in 14 patients. In four of the 14 patients, retinal hemorrhage was also observed simultaneously or sequentially. Two of the 16 patients who developed retinopathy were diagnosed by retinal hemorrhage without cotton wool spots. One patient (not diabetic or hypertensive) had

<table>
<thead>
<tr>
<th>Table 1 Clinical data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical data</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Sex (M/F)</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Retinopathy</td>
</tr>
<tr>
<td>Laterality (bilateral/unilateral)</td>
</tr>
<tr>
<td>Hemorrhage</td>
</tr>
<tr>
<td>Cotton wool spots</td>
</tr>
<tr>
<td>Cystoid macular edema</td>
</tr>
</tbody>
</table>
Interferon-associated retinopathy was first recognized in 1990 when Ikebe and associates reported a 39-year-old patient who developed retinal hemorrhages and cotton wool spots following intravenous administration of interferon. The underlying mechanisms of interferon-induced retinopathy are not completely understood. Guyer et al had proposed an immune complex deposition causing occlusion of retinal capillaries leading to cotton wool spot formation. On the other hand, an ischemic insult, similar to that seen in hypertensive and diabetic patients could be another potential mechanism by which these changes develop.

Some studies have shown a relatively higher incidence of retinopathy (symptomatic or asymptomatic) ranging from 19% to 64% during treatment with interferon. Panetta and Gilani and Cuthbertson et al show relatively lower incidences of retinopathy (3.8% and 6.25%, respectively). The incidence of retinopathy in our study was 16%.

Similar to other studies, our study also shows that retinal changes usually develop within the first 3 months of interferon treatment, a fact that may favor an immune etiology rather than a cumulative effect of interferon leading to the development of retinopathy.

Retinopathy developed by week 14 in most of the patients (13/16, 81.25%) after the start of therapy and disappeared in the majority of the patients (11/16, 68.75%) during the 4–8 week period in which the patients were receiving the treatment. This suggests that treatment can be continued despite the development of retinopathy in many patients. However, two patients who developed cotton wool spots early in the therapy (2 weeks) thereafter suffered from retinal hemorrhage in a prolonged manner. Therefore, patients who develop cotton wool spots early on during therapy should be carefully monitored.

However, as reported in previous studies, most of the patients with retinopathy in this study were asymptomatic. This study confirms previous reports that retinopathy is a temporary and asymptomatic complication of interferon therapy.

There is no classification for IFN-induced retinopathy, like diabetic retinopathy. Therefore there is no rule for
suspending the use of interferon in patients who develop retinopathy or any other ocular side effects. It’s commonly agreed among authors that careful monitoring should be performed in the presence of any ocular sign, even without symptoms.\textsuperscript{18}

**Conclusion**

Interferon therapy can lead to retinopathy which is almost reversible and dose related. Periodic fundoscopic examinations help in early detection and prevent progression to permanent visual loss.
Disclosure
The authors report no conflicts of interest in this work.

References